Login Register Cart 0
Review Article

治疗老年黄斑变性的药理进展

卷 27, 期 4, 2020

页: [583 - 598] 页: 16

弟呕挨: 10.2174/0929867326666190726121711

价格: $65

摘要

与年龄有关的黄斑变性是一种获得性的变性疾病，是导致老年人严重视力下降的原因。有两种类型：干性老年黄斑变性和湿性老年黄斑变性。它的处理已得到改进，并在将来尝试进行定制。这篇综述的目的是总结治疗与年龄有关的黄斑变性的药理学进展。对于干性AMD，尚无有效的治疗方法可降低其进展。然而，一些分子，如兰帕珠单抗和依库丽单抗，尽管疗效低下，但仍在研究中。在此，为了防止干燥的AMD进展，最重要的研究建议增加抗氧化剂的摄入并戒烟。另一方面，湿性AMD有更发达的治疗方法。如今，金标准治疗是抗VEGF注射。但是，目前正在研究更有效的分子。干AMD和湿AMD有不同的分子正在研究中。这个事实可以帮助我们用更有效，更持久的药物治疗患者，但是需要更多的临床试验和安全性研究才能达到最佳治疗效果。

关键词: 年龄有关黄斑变性，脉络膜新生血管，药理学，血管内皮生长因子，分子，治疗。

« Previous Next »
[1]
Evans, J.R.; Fletcher, A.E.; Wormald, R.P.L. Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC trial of assessment and management of older people in the community. Br. J. Ophthalmol., 2004, 88(3), 365-370.
[http://dx.doi.org/10.1136/bjo.2003.019927] [PMID: 14977771]
[2]
Luttrull, J.K.; Sinclair, S.H.; Elmann, S.; Glaser, B.M. Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD. PLoS One, 2018, 13(8), e0202097
[http://dx.doi.org/10.1371/journal.pone.0202097] [PMID: 30138455]
[3]
Santarelli, M.; Diplotti, L.; Samassa, F.; Veritti, D.; Kuppermann, B.D.; Lanzetta, P. Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opin. Pharmacother., 2015, 16(12), 1769-1781.
[http://dx.doi.org/10.1517/14656566.2015.1067679] [PMID: 26165696]
[4]
Al-Zamil, W.M.; Yassin, S.A. Recent developments in age-related macular degeneration: a review. Clin. Interv. Aging, 2017, 12, 1313-1330.
[http://dx.doi.org/10.2147/CIA.S143508] [PMID: 28860733]
[5]
Brandl, C.; Zimmermann, M.E.; Günther, F.; Barth, T.; Olden, M.; Schelter, S.C.; Kronenberg, F.; Loss, J.; Küchenhoff, H.; Helbig, H.; Weber, B.H.F.; Stark, K.J.; Heid, I.M. On the impact of different approaches to classify age-related macular degeneration: results from the German AugUR study. Sci. Rep., 2018, 8(1), 8675.
[http://dx.doi.org/10.1038/s41598-018-26629-5] [PMID: 29875478]
[6]
Ho, E.X.P.; Cheung, C.M.G.; Sim, S.; Chu, C.W.; Wilm, A.; Lin, C.B.; Mathur, R.; Wong, D.; Chan, C.M.; Bhagarva, M.; Laude, A.; Lim, T.H.; Wong, T.Y.; Cheng, C.Y.; Davila, S.; Hibberd, M. Human pharyngeal microbiota in age-related macular degeneration. PLoS One, 2018, 13(8), e0201768
[http://dx.doi.org/10.1371/journal.pone.0201768] [PMID: 30089174]
[7]
Garrity, S.T.; Sarraf, D.; Freund, K.B.; Sadda, S.R. Multimodal imaging of nonneovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci., 2018, 59(4), AMD48-AMD64.
[http://dx.doi.org/10.1167/iovs.18-24158] [PMID: 30025107]
[8]
Shams Najafabadi, H.; Daftarian, N.; Ahmadieh, H.; Soheili, Z.S. Pharmacologic treatment of wet type age-related macular degeneration; current and evolving therapies. Arch. Iran Med., 2017, 20(8), 525-537.
[PMID: 28846017]
[9]
Davis, M.D.; Gangnon, R.E.; Lee, L.Y.; Hubbard, L.D.; Klein, B.E.K.; Klein, R.; Ferris, F.L.; Bressler, S.B.; Milton, R.C. Age-Related Eye Disease Study Group. The age-related eye disease study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch. Ophthalmol., 2005, 123(11), 1484-1498.
[http://dx.doi.org/10.1001/archopht.123.11.1484] [PMID: 16286610]
[10]
Ferris, F.L.; Davis, M.D.; Clemons, T.E.; Lee, L.Y.; Chew, E.Y.; Lindblad, A.S.; Milton, R.C.; Bressler, S.B.; Klein, R. Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS report No. 18. Arch. Ophthalmol., 2005, 123(11), 1570-1574.
[http://dx.doi.org/10.1001/archopht.123.11.1570] [PMID: 16286620]
[11]
Farecki, M.L.; Gutfleisch, M.; Faatz, H.; Rothaus, K.; Heimes, B.; Spital, G.; Lommatzsch, A.; Pauleikhoff, D. Characteristics of type 1 and 2 CNV in exudative AMD in OCT-Angiography. Graefes Arch. Clin. Exp. Ophthalmol., 2017, 255(5), 913-921.
[http://dx.doi.org/10.1007/s00417-017-3588-y] [PMID: 28233061]
[12]
Spaide, R.F. Improving the age-related macular degeneration construct: a new classification system. Retina, 2018, 38(5), 891-899.
[http://dx.doi.org/10.1097/IAE.0000000000001732] [PMID: 28557901]
[13]
Teo, K.Y.C.; Gillies, M.; Fraser-Bell, S. The use of vascular endothelial growth factor inhibitors and complementary treatment options in polypoidal choroidal vasculopathy: a subtype of neovascular age-related macular degeneration. Int. J. Mol. Sci., 2018, 19(9), 2611.
[http://dx.doi.org/10.3390/ijms19092611] [PMID: 30177632]
[14]
Cheung, C.M.G.; Lee, W.K.; Koizumi, H.; Dansingani, K.; Lai, T.Y.Y.; Freund, K.B. Pachychoroid disease. Eye (Lond.), 2018, 33(1), 14-33.
[http://dx.doi.org/http://dx.doi.org/10.1038/s41433-018-0158-4] [PMID: 29995841]
[15]
Alshahrani, S.T.; Al Shamsi, H.N.; Kahtani, E.S.; Ghazi, N.G. Spectral-domain optical coherence tomography findings in polypoidal choroidal vasculopathy suggest a type 1 neovascular growth pattern. Clin. Ophthalmol., 2014, 8, 1689-1695.
[http://dx.doi.org/10.2147/OPTH.S68471] [PMID: 25214762]
[16]
Wright, C.B.; Ambati, J. Dry age-related macular degeneration pharmacology. Handb. Exp. Pharmacol., 2017, 242, 321-336.
[http://dx.doi.org/10.1007/164_2016_36] [PMID: 27900609]
[17]
Wong, P.; Markey, M.; Rapp, C.M.; Darrow, R.M.; Ziesel, A.; Organisciak, D.T. Enhancing the efficacy of AREDS antioxidants in light-induced retinal degeneration. Mol. Vis., 2017, 23, 718-739.
[PMID: 29062223]
[18]
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol., 2001, 119(10), 1417-1436.
[http://dx.doi.org/10.1001/archopht.119.10.1417] [PMID: 11594942]
[19]
Chew, E.Y.; Clemons, T.; SanGiovanni, J.P.; Danis, R.; Domalpally, A.; McBee, W.; Sperduto, R.; Ferris, F.L. AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology, 2012, 119(11), 2282-2289.
[http://dx.doi.org/10.1016/j.ophtha.2012.05.027] [PMID: 22840421]
[20]
Aronow, M.E.; Chew, E.Y. Age-related eye disease study 2: perspectives, recommendations, and unanswered questions. Curr. Opin. Ophthalmol., 2014, 25(3), 186-190.
[http://dx.doi.org/10.1097/ICU.0000000000000046] [PMID: 24614146]
[21]
Evans, J.R. Ginkgo biloba extract for age-related macular degeneration. Cochrane Database Syst. Rev., 2013, (1), CD001775
[http://dx.doi.org/10.1002/14651858.CD001775.pub2] [PMID: 23440785]
[22]
Pinazo-Durán, M.D.; Gómez-Ulla, F.; Arias, L.; Araiz, J.; Casaroli-Marano, R.; Gallego-Pinazo, R.; García-Medina, J.J.; López-Gálvez, M.I.; Manzanas, L.; Salas, A.; Zapata, M.; Diaz-Llopis, M.; García-Layana, A. Do nutritional supplements have a role in age macular degeneration prevention? J. Ophthalmol., 2014, 2014, 901686
[http://dx.doi.org/10.1155/2014/901686] [PMID: 24672708]
[23]
Velilla, S.; García-Medina, J.J.; García-Layana, A.; Dolz-Marco, R.; Pons-Vázquez, S.; Pinazo-Durán, M.D.; Gómez-Ulla, F.; Arévalo, J.F.; Díaz-Llopis, M.; Gallego-Pinazo, R. Smoking and age-related macular degeneration: review and update. J. Ophthalmol., 2013., 895147
[http://dx.doi.org/10.1155/2013/895147] [PMID: 24368940]
[24]
Yaspan, B.L.; Williams, D.F.; Holz, F.G.; Regillo, C.D.; Li, Z.; Dressen, A.; van Lookeren Campagne, M.; Le, K.N.; Graham, R.R.; Beres, T.; Bhangale, T.R.; Honigberg, L.A.; Smith, A.; Henry, E.C.; Ho, C.; Strauss, E.C. MAHALO Study Investigators. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci. Transl. Med., 2017, 9(395), eaaf1443
[http://dx.doi.org/10.1126/scitranslmed.aaf1443] [PMID: 28637922]
[25]
Holz, F.G.; Sadda, S.R.; Busbee, B.; Chew, E.Y.; Mitchell, P.; Tufail, A.; Brittain, C.; Ferrara, D.; Gray, S.; Honigberg, L.; Martin, J.; Tong, B.; Ehrlich, J.S.; Bressler, N.M. Chroma and Spectri Study Investigators. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri Phase 3 randomized clinical trials. JAMA Ophthalmol., 2018, 136(6), 666-677.
[http://dx.doi.org/10.1001/jamaophthalmol.2018.1544] [PMID: 29801123]
[26]
Yehoshua, Z.; de Amorim Garcia Filho, C.A.; Nunes, R.P.; Gregori, G.; Penha, F.M.; Moshfeghi, A.A.; Zhang, K.; Sadda, S.; Feuer, W.; Rosenfeld, P.J. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology, 2014, 121(3), 693-701.
[http://dx.doi.org/10.1016/j.ophtha.2013.09.044] [PMID: 24289920]
[27]
Luttrull, J.K.; Margolis, B.W.L. Functionally guided retinal protective therapy for dry age-related macular and inherited retinal degenerations: a pilot study. Invest. Ophthalmol. Vis. Sci., 2016, 57(1), 265-275.
[http://dx.doi.org/10.1167/iovs.15-18163] [PMID: 26818793]
[28]
Virgili, G.; Michelessi, M.; Parodi, M.B.; Bacherini, D.; Evans, J.R. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst. Rev., 2015, 10(3), CD006537
[http://dx.doi.org/10.1002/14651858.CD006537.pub3] [PMID: 26493180]
[29]
Mirshahi, A.; Azimi, P.; Abdolahi, A.; Mirshahi, R.; Abdollahian, M. Oral doxycycline reduces the total number of intraocular bevacizumab injections needed to control neovascular age-related macular degeneration. Med. Hypothesis Discov. Innov. Ophthalmol., 2017, 6(2), 23-29.
[PMID: 29367931]
[30]
Clinical study to evaluate treatment with oracea® for geographic atrophy (toga). Available at: https://clinicaltrials.gov/ct2/show/NCT01782989 (Accessed: September 5, 2018).
[31]
A Study of MTP-131 topical ophthalmic solution in subjects with diabetic macular edema and non-exudative intermediate age-related macular degeneration. Available at: https://clinicaltrials.gov/ct2/show/NCT02314299 (Accessed: September 5, 20180.
[32]
Chichagova, V.; Hallam, D.; Collin, J.; Zerti, D.; Dorgau, B.; Felemban, M.; Lako, M.; Steel, D.H. Cellular regeneration strategies for macular degeneration: past, present and future. Eye (Lond.), 2018, 32(5), 946-971.
[http://dx.doi.org/10.1038/s41433-018-0061-z] [PMID: 29503449]
[33]
Fine, S.L. Macular photocoagulation study. Arch. Ophthalmol., 1980, 1980(98), 832.
[http://dx.doi.org/10.1001/archopht.1980.01020030826002] [PMID: 6155116]
[34]
L.J.S. Miller M.D. Pharmacological treatments for AMD. Available at: https://www.reviewofophthalmology.com/article/pharmacological-treatments-for-amd (Accessed: August 11, 2018).
[35]
Su, Y.; Wu, J.; Gu, Y. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: a systematic review and meta-analysis. Photodiagn. Photodyn. Ther., 2018, 22, 263-273.
[http://dx.doi.org/10.1016/j.pdpdt.2018.05.002] [PMID: 29753123]
[36]
Maguire, M.G.; Martin, D.F.; Ying, G.S.; Jaffe, G.J.; Daniel, E.; Grunwald, J.E.; Toth, C.A.; Ferris, F.L., III; Fine, S.L. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology, 2016, 123(8), 1751-1761.
[http://dx.doi.org/10.1016/j.ophtha.2016.03.045] [PMID: 27156698]
[37]
Radhika, M.; Mithal, K.; Bawdekar, A.; Dave, V.; Jindal, A.; Relhan, N.; Albini, T.; Pathengay, A.; Flynn, H.W. Pharmacokinetics of intravitreal antibiotics in endophthalmitis. J. Ophthalmic Inflamm. Infect., 2014, 4, 22.
[http://dx.doi.org/10.1186/s12348-014-0022-z] [PMID: 25667683]
[38]
Fernández-Ferreiro, A.; Silva-Rodríguez, J.; Otero-Espinar, F.J.; González-Barcia, M.; Lamas, M.J.; Ruibal, A.; Luaces-Rodriguez, A.; Vieites-Prado, A.; Sobrino, T.; Herranz, M.; García-Varela, L.; Blanco-Mendez, J.; Gil-Martínez, M.; Pardo, M.; Moscoso, A.; Medín-Aguerre, S.; Pardo-Montero, J.; Aguiar, P. Positron emission tomography for the development and characterization of corneal permanence of ophthalmic pharmaceutical formulations. Invest. Ophthalmol. Vis. Sci., 2017, 58(2), 772-780.
[http://dx.doi.org/10.1167/iovs.16-20766 https://doi.org/10.1167/iovs.16-20766] [PMID: 28146242]
[39]
Fernández-Ferreiro, A.; González-Barcia, M.; Otero Espinar, F.J.; Blanco Méndez, J.; Lamas, M.J. Ophthalmic formulations new goals. Farm. Hosp., 2016, 40(1), 1-2.
[http://dx.doi.org/10.7399/fh.2016.40.1.10417] [PMID: 26882828]
[40]
Gaudana, R.; Ananthula, H.K.; Parenky, A.; Mitra, A.K. Ocular drug delivery. AAPS J., 2010, 12(3), 348-360.
[http://dx.doi.org/10.1208/s12248-010-9183-3] [PMID: 20437123]
[41]
Fernández-Ferreiro, A.; Luaces-Rodríguez, A.; Aguiar, P.; Pardo-Montero, J.; González-Barcia, M.; García-Varela, L.; Herranz, M.; Silva-Rodríguez, J.; Gil-Martínez, M.; Bermúdez, M.A.; Vieites-Prado, A.; Blanco-Méndez, J.; Lamas, M.J.; Gómez-Ulla, F.; Ruibal, Á.; Otero-Espinar, F.J.; González, F. Preclinical PET study of intravitreal injections. Invest. Ophthalmol. Vis. Sci., 2017, 58(7), 2843-2851.
[http://dx.doi.org/10.1167/iovs.17-21812] [PMID: 28570736]
[42]
Luaces-Rodríguez, A.; González-Barcia, M.; Blanco-Teijeiro, M.J.; Gil-Martínez, M.; Gonzalez, F.; Gómez-Ulla, F.; Lamas, M.J.; Otero-Espinar, F.J.; Fernández-Ferreiro, A. Review of intraocular pharmacokinetics of anti-infectives commonly used in the treatment of infectious endophthalmitis. Pharmaceutics, 2018, 10(2), E66
[http://dx.doi.org/10.3390/pharmaceutics10020066] [PMID: 29844284]
[43]
Dossarps, D.; Bron, A.M.; Koehrer, P.; Aho-Glélé, L.S.; Creuzot-Garcher, C.; Berthon, L.; Maftouhi, Q.E.; Bakhti, A.; Conrath, J. FRCR net (French Retina specialists net). Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am. J. Ophthalmol., 2015, 160(1), 17-25.
[http://dx.doi.org/10.1016/j.ajo.2015.04.013] [PMID: 25892127]
[44]
Ross, A.E.; Bengani, L.C.; Tulsan, R.; Maidana, D.E.; Salvador-Culla, B.; Kobashi, H.; Kolovou, P.E.; Zhai, H.; Taghizadeh, K.; Kuang, L.; Mehta, M.; Vavvas, D.G.; Kohane, D.S.; Ciolino, J.B. Topical sustained drug delivery to the retina with a drug-eluting contact lens. Biomaterials, 2019., 217119285
[http://dx.doi.org/10.1016/j.biomaterials.2019.119285] [PMID: 31299627]
[45]
Ramulu, P.Y.; Do, D.V.; Corcoran, K.J.; Corcoran, S.L.; Robin, A.L. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch. Ophthalmol., 2010, 128(10), 1335-1340.
[http://dx.doi.org/10.1001/archophthalmol.2010.224] [PMID: 20938004]
[46]
Schlottmann, P.G.; Alezzandrini, A.A.; Zas, M.; Rodriguez, F.J.; Luna, J.D.; Wu, L. New treatment modalities for neovascular age-related macular degeneration. Asia Pac. J. Ophthalmol. (Phila.), 2017, 6(6), 514-519.
[http://dx.doi.org/10.22608/APO.2017258] [PMID: 28933517]
[47]
Okada, M.; Kandasamy, R.; Chong, E.W.; McGuiness, M.; Guymer, R.H. The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am. J. Ophthalmol., 2018, 192, 184-197.
[http://dx.doi.org/10.1016/j.ajo.2018.05.026] [PMID: 29885297]
[48]
Nguyen, C.L.; Oh, L.J.; Wong, E.; Wei, J.; Chilov, M. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol., 2018, 18(1), 130.
[http://dx.doi.org/10.1186/s12886-018-0785-3] [PMID: 29843663]
[49]
Doggrell, S.A. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin. Pharmacother., 2005, 6(8), 1421-1423.
[http://dx.doi.org/10.1517/14656566.6.8.1421] [PMID: 16013991]
[50]
Jaffe, G.J.; Ying, G-S.; Toth, C.A.; Daniel, E.; Grunwald, J.E.; Martin, D.F.; Maguire, M.G. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology, 2019, 126(2), 252-260.
[http://dx.doi.org/10.1016/j.ophtha.2018.08.035] [PMID: 30189282]
[51]
Patel, R.D.; Momi, R.S.; Hariprasad, S.M. Review of ranibizumab trials for neovascular age-related macular degeneration. Semin. Ophthalmol., 2011, 26(6), 372-379.
[http://dx.doi.org/10.3109/08820538.2011.570845] [PMID: 22044335]
[52]
Bressler, N.M.; Chang, T.S.; Suñer, I.J.; Fine, J.T.; Dolan, C.M.; Ward, J.; Ianchulev, T. MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology, 2010, 117(4), 747-756.
[http://dx.doi.org/10.1016/j.ophtha.2009.09.002] [PMID: 20189654]
[53]
Chang, T.S.; Bressler, N.M.; Fine, J.T.; Dolan, C.M.; Ward, J.; Klesert, T.R. MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch. Ophthalmol., 2007, 125(11), 1460-1469.
[http://dx.doi.org/10.1001/archopht.125.11.1460] [PMID: 17998507]
[54]
Bhisitkul, R.B.; Mendes, T.S.; Rofagha, S.; Enanoria, W.; Boyer, D.S.; Sadda, S.R.; Zhang, K. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVENUP study. Am. J. Ophthalmol, 2015, 159(5), 915-924.
[http://dx.doi.org/10.1016/j.ajo.2015.01.032] [PMID: 25640411]
[55]
Arias, L.; Ruiz-Moreno, J.M.; Gómez-Ulla, F.; Fernández, M.; Montero, J. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina, 2009, 29(10), 1444-1449.
[http://dx.doi.org/10.1097/IAE.0b013e3181ae712d] [PMID: 19730163]
[56]
García-Layana, A.; Figueroa, M.S.; Araiz, J.; Ruiz-Moreno, J.M.; Gómez-Ulla, F.; Arias-Barquet, L.; Reiter, N. Treatment of exudative age-related macular degeneration: focus on aflibercept. Drugs Aging, 2015, 32(10), 797-807.
[http://dx.doi.org/10.1007/s40266-015-0300-y] [PMID: 26442858]
[57]
Heier, J.S.; Brown, D.M.; Chong, V.; Korobelnik, J-F.; Kaiser, P.K.; Nguyen, Q.D.; Kirchhof, B.; Ho, A.; Ogura, Y.; Yancopoulos, G.D.; Stahl, N.; Vitti, R.; Berliner, A.J.; Soo, Y.; Anderesi, M.; Groetzbach, G.; Sommerauer, B.; Sandbrink, R.; Simader, C.; Schmidt-Erfurth, U. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology, 2012, 119(12), 2537-2548.
[http://dx.doi.org/10.1016/j.ophtha.2012.09.006] [PMID: 23084240]
[58]
Martin, D.F.; Maguire, M.G.; Ying, G.S.; Grunwald, J.E.; Fine, S.L.; Jaffe, G.J. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 2011, 364(20), 1897-1908.
[http://dx.doi.org/10.1056/NEJMoa1102673] [PMID: 21526923]
[59]
Gillies, M.C.; Hunyor, A.P.; Arnold, J.J.; Guymer, R.H.; Wolf, S.; Ng, P.; Pecheur, F.L.; McAllister, I.L. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol., 2019, 137(4), 372-379.
[http://dx.doi.org/10.1001/jamaophthalmol.2018.6776] [PMID: 30676617]
[60]
Chakravarthy, U.; Harding, S.P.; Rogers, C.A.; Downes, S.M.; Lotery, A.J.; Wordsworth, S.; Reeves, B.C. IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology, 2012, 119(7), 1399-1411.
[http://dx.doi.org/10.1016/j.ophtha.2012.04.015] [PMID: 22578446]
[61]
Schmidt-Erfurth, U.; Garcia-Arumi, J.; Bandello, F.; Berg, K.; Chakravarthy, U.; Gerendas, B.S.; Jonas, J.; Larsen, M.; Tadayoni, R.; Loewenstein, A. Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica, 2017, 237(4), 185-222.
[http://dx.doi.org/10.1159/000458539] [PMID: 28423385]
[62]
García-Layana, A.; Figueroa, M.S.; Arias, L.; Araiz, J.; Ruiz-Moreno, J.M.; García-Arumí, J.; Gómez-Ulla, F.; López-Gálvez, M.I.; Cabrera-López, F.; García-Campos, J.M.; Monés, J.; Cervera, E.; Armadá, F.; Gallego-Pinazo, R. Individualized therapy with ranibizumab in wet age-related macular degeneration. J. Ophthalmol., 2015, 2015, 412903
[http://dx.doi.org/10.1155/2015/412903] [PMID: 26491550]
[63]
Haga, A.; Kawaji, T.; Ideta, R.; Inomata, Y.; Tanihara, H. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration. Acta Ophthalmol., 2018, 96(3), e393-e398.
[http://dx.doi.org/10.1111/aos.13607] [PMID: 29220114]
[64]
Parvin, P.; Zola, M.; Dirani, A.; Ambresin, A.; Mantel, I. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. Graefes Arch. Clin. Exp. Ophthalmol., 2017, 255(11), 2127-2134.
[http://dx.doi.org/10.1007/s00417-017-3762-2] [PMID: 28798980]
[65]
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640735/ (Accessed: September 23, 2018).
[66]
Future perspectives, A.M.D. New promising drugs., Available at: www.amdbook.org/content/amd-future-perspec-tives-new-promising-drugs (Accessed September 22, 2018).
[67]
Dugel, P.U.; Koh, A.; Ogura, Y.; Jaffe, G.J.; Schmidt-Erfurth, U.; Brown, D.M.; Gomes, A.V.; Warburton, J.; Weichselberger, A.; Holz, F.G. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology, 2020, 127(1), 72-84.
[http://dx.doi.org/10.1016/j.ophtha.2019.04.017] [PMID: 30986442]
[68]
Dugel, P.U.; Jaffe, G.J.; Sallstig, P.; Warburton, J.; Weichselberger, A.; Wieland, M.; Singerman, L. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology, 2017, 124(9), 1296-1304.
[http://dx.doi.org/10.1016/j.ophtha.2017.03.057] [PMID: 28551167]
[69]
Stewart, M.W. Extended duration vascular endothelial growth factor inhibition in the eye: failures, successes, and future possibilities. Pharmaceutics, 2018, 10(1), E21
[http://dx.doi.org/10.3390/pharmaceutics10010021] [PMID: 29382038]
[70]
Li, X.; Xu, G.; Wang, Y.; Xu, X.; Liu, X.; Tang, S.; Zhang, F.; Zhang, J.; Tang, L.; Wu, Q.; Luo, D.; Ke, X. AURORA Study Group. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology, 2014, 121(9), 1740-1747.
[http://dx.doi.org/10.1016/j.ophtha.2014.03.026] [PMID: 24793528]
[71]
Lu, X.; Sun, X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des. Devel. Ther., 2015, 9, 2311-2320.
[http://dx.doi.org/10.2147/DDDT.S67536] [PMID: 25960634]
[72]
Mansour, A.M.; Ashraf, M.; Charbaji, A.; Younis, M.H.; Souka, A.A.; Dogra, A.; Mansour, H.A.; Chhablani, J. Ziv-aflibercept study group investigators. Two-year outcomes of intravitreal ziv-aflibercept. Br. J. Ophthalmol., 2018, 102(10), 1387-1390.
[http://dx.doi.org/10.1136/bjophthalmol-2017-311591] [PMID: 29317400]
[73]
Hussain, R.M.; Ciulla, T.A. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin. Emerg. Drugs, 2017, 22(3), 235-246.
[http://dx.doi.org/10.1080/14728214.2017.1362390] [PMID: 28756707]
[74]
A dose ranging study of OPT-302 With ranibizumab in neovascular (wet) AMD. Available at: https://clinical-trials.gov/ct2/show/NCT03345082 (Accessed: September 22, 2018).
[75]
Jackson, T.L.; Boyer, D.; Brown, D.M.; Chaudhry, N.; Elman, M.; Liang, C.; O’Shaughnessy, D.; Parsons, E.C.; Patel, S.; Slakter, J.S.; Rosenfeld, P.J. Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study. JAMA Ophthalmol., 2017, 135(7), 761-767.
[http://dx.doi.org/10.1001/jamaophthalmol.2017.1571] [PMID: 28570723]
[76]
Pecen, P.E.; Kaiser, P.K. Current phase 1/2 research for neovascular age-related macular degeneration. Curr. Opin. Ophthalmol., 2015, 26(3), 188-193.
[http://dx.doi.org/10.1097/ICU.0000000000000147] [PMID: 25822255]
[77]
Study of PAN-90806 Eye Drops. Suspension for Neovascular AMD., Available at: https://clinicaltrials.gov/ct2/show/record/NCT03479372 (Accessed: September 23, 2018).
[78]
Zimmermann, T.; Höchel, J.; Becka, M.; Boettger, M.K.; Rohde, B.; Schug, B.; Kunert, K.S.; Donath, F. Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers. Br. J. Clin. Pharmacol., 2018, 84(5), 865-875.
[http://dx.doi.org/10.1111/bcp.13502] [PMID: 29315699]
[79]
Regorafenib eye drops: investigation of efficacy and safety in neovascular age related macular degeneration - study results. Available at: https://clinicaltrials.gov/ct2/show/results/NCT02222207 (Accessed: September 23, 2018).
[80]
LHA510 Proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration - study results. Available at: https://clinicaltrials.gov/ct2/show/results/NCT02355028 (Accessed: September 23, 2018).
[81]
Malamos, P.; Tservakis, I.; Kanakis, M.; Koutsiouki, C.; Kiskira, E.; Mylonas, G.; Lakoumentas, J.; Georgalas, I. Long-term results of combination treatment with single-dose ranibizumab plus photodynamic therapy for retinal angiomatous proliferation. Ophthalmologica, 2018, 240(4), 213-221.
[http://dx.doi.org/10.1159/000487610] [PMID: 29768269]
[82]
Arias, L.; Gómez-Ulla, F.; Ruiz-Moreno, J.M. Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation. Clin. Ophthalmol., 2016, 10, 861-869.
[http://dx.doi.org/10.2147/OPTH.S106092] [PMID: 27274190]
[83]
Lee, W.K.; Iida, T.; Ogura, Y.; Chen, S-J.; Wong, T.Y.; Mitchell, P.; Cheung, G.C.M.; Zhang, Z.; Leal, S.; Ishibashi, T. PLANET Investigators. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET Study: a randomized clinical trial. JAMA Ophthalmol., 2018, 136(7), 786-793.
[http://dx.doi.org/10.1001/jamaophthalmol.2018.1804] [PMID: 29801063]
[84]
Freiberg, F.J.; Michels, S.; Muldrew, A.; Slakter, J.; O’Shaughnessy, D.; Czeszynski, A.; Danielson, L.; Jackson, T.L.; Chakravarthy, U. Microvascular abnormalities secondary to radiation therapy in neovascular age-related macular degeneration: findings from the INTREPID clinical trial. Br. J. Ophthalmol., 2019, 103(4), 469-474.
[http://dx.doi.org/10.1136/bjophthalmol-2018-311865] [PMID: 29930098]
[85]
Arslan, J.; Baird, P.N. Changing vision: a review of pharmacogenetic studies for treatment response in age-related macular degeneration patients. Pharmacogenomics, 2018, 19(5), 435-461.
[http://dx.doi.org/10.2217/pgs-2017-0183] [PMID: 29577807]
[86]
Cobos, E.; Recalde, S.; Anter, J.; Hernandez-Sanchez, M.; Barreales, C.; Olavarrieta, L.; Valverde, A.; Suarez-Figueroa, M.; Cruz, F.; Abraldes, M.; Pérez-Pérez, J.; Fernández-Robredo, P.; Arias, L.; García-Layana, A. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration. Acta Ophthalmol., 2018, 96(2), e201-e212.
[http://dx.doi.org/10.1111/aos.13519] [PMID: 28926193]
[87]
Ueda-Consolvo, T.; Hayashi, A.; Ozaki, M.; Nakamura, T.; Yagou, T.; Abe, S. The relationship between vascular endothelial dysfunction and treatment frequency in neovascular age-related macular degeneration. Jpn. J. Ophthalmol., 2017, 61(4), 347-353.
[http://dx.doi.org/10.1007/s10384-017-0515-z] [PMID: 28447271]
[88]
Lorés-Motta, L.; Riaz, M.; Grunin, M.; Corominas, J.; van Asten, F.; Pauper, M.; Leenders, M.; Richardson, A.J.; Muether, P.; Cree, A.J.; Griffiths, H.L.; Pham, C.; Belanger, M-C.; Meester-Smoor, M.A.; Ali, M.; Heid, I.M.; Fritsche, L.G.; Chakravarthy, U.; Gale, R.; McKibbin, M.; Inglehearn, C.F.; Schlingemann, R.O.; Omar, A.; Chen, J.; Koenekoop, R.K.; Fauser, S.; Guymer, R.H.; Hoyng, C.B.; de Jong, E.K.; Lotery, A.J.; Mitchell, P.; den Hollander, A.I.; Baird, P.N.; Chowers, I. Association of genetic variants with response to anti-vascular endothelial growth factor therapy in age-related macular degeneration. JAMA Ophthalmol., 2018, 136(8), 875-884.
[http://dx.doi.org/10.1001/jamaophthalmol.2018.2019] [PMID: 29852030]
[89]
Valverde-Megías, A.; Veganzones-de-Castro, S.; Donate-López, J.; Maestro-de-Las-Casas, M.L.; Megías-Fresno, A.; García-Feijoo, J. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up. Graefes Arch. Clin. Exp. Ophthalmol., 2017, 255(11), 2091-2098.
[http://dx.doi.org/10.1007/s00417-017-3748-0] [PMID: 28744656]
[90]
Brión, M.; Sanchez-Salorio, M.; Cortón, M.; de la Fuente, M.; Pazos, B.; Othman, M.; Swaroop, A.; Abecasis, G.; Sobrino, B.; Carracedo, A. Spanish multi-centre group of AMD. Genetic association study of age-related macular degeneration in the Spanish population. Acta Ophthalmol., 2011, 89(1), e12-e22.
[http://dx.doi.org/10.1111/j.1755-3768.2010.02040.x] [PMID: 21106043]
[91]
García-Quintanilla, L.; Maroñas, O.; Luaces-Rodriguez, A.; Fernández-Ferreiro, A.; LaTorre Pellicer, A.; Abraldes, M.; Lamas, M.; Carracedo, A. Anti-VEGF treatment and response in age-related macular degeneration: disease’s susceptibility, pharmacogenetics, and pharmacokinetics. Curr. Med. Chem., In Press
[http://dx.doi.org/10.2174/0929867326666190711105325] [PMID: 31296152]
[92]
Guzman-Aranguez, A.; Loma, P.; Pintor, J. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br. J. Pharmacol., 2013, 170(4), 730-747.
[http://dx.doi.org/10.1111/bph.12330] [PMID: 23937539]
[93]
Safety efficacy study evaluating the combination of bevasiranib lucentis therapy in wet AMD - Study Results - Clinical Trials. Available at: https://clinicaltrials.gov/ct2/show/results/NCT00499590 (Accessed September 23, 2018)
[94]
Hernández-Zimbrón, L.F.; Zamora-Alvarado, R.; Ochoa-De la Paz, L.; Velez-Montoya, R.; Zenteno, E.; Gulias-Cañizo, R.; Quiroz-Mercado, H.; Gonzalez-Salinas, R. Age-related macular degeneration: new paradigms for treat-ment and management of AMD. Oxid. Med. Cell. Longev., 2018, 2018, 8374647
[http://dx.doi.org/https://doi.org/10.1155/2018/8374647] [PMID: 29484106]
[95]
Kaiser, P.K.; Symons, R.C.A.; Shah, S.M.; Quinlan, E.J.; Tabandeh, H.; Do, D.V.; Reisen, G.; Lockridge, J.A.; Short, B.; Guerciolini, R.; Nguyen, Q.D. Sirna-027 Study Investigators. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am. J. Ophthalmol., 2010, 150(1), 33-39.
[http://dx.doi.org/10.1016/j.ajo.2010.02.006] [PMID: 20609706]
[96]
Nguyen, Q.D.; Schachar, R.A.; Nduaka, C.I.; Sperling, M.; Klamerus, K.J.; Chi-Burris, K.; Yan, E.; Paggiarino, D.A.; Rosenblatt, I.; Aitchison, R.; Erlich, S.S. MONET Clinical Study Group. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology, 2012, 119(9), 1867-1873.
[http://dx.doi.org/10.1016/j.ophtha.2012.03.043] [PMID: 22683252]
[97]
A depot formulation of sunitinib malate (GB-102) in subjects with neovascular (Wet) age-related macular degeneration. Available at: https://clinicaltrials.gov/ct2/show/NCT03249740 (Accessed: September 23, 2018).
[98]
Study of the intravitreal implantation of NT-503-3 encapsulated cell technology (ECT) for the treatment of recurrent choroidal neovascularization (CNV) secondary to agerelated macular degeneration (AMD). Available at: https://clinicaltrials.gov/ct2/show/NCT02228304 (Accessed: September 23, 2018)
[99]
Guerrero-Naranjo, J.L.; Quiroz-Mercado, H.; Sanchez-Bermudez, G.; Schoonewolff, F.; Longoria, S.S.; Vera, R.R.; Tao, W.; Beckman, R.; Morales-Canton, V. Safety of implantation of the NT-503 device in patients with choroidal neovascularization secondary to age-related macular degeneration. Invest. Ophthalmol. Vis. Sci., 2013, 54(15), 3298-3298.
[100]
Adamson, P.; Wilde, T.; Dobrzynski, E.; Sychterz, C.; Polsky, R.; Kurali, E.; Haworth, R.; Tang, C-M.; Korczynska, J.; Cook, F.; Papanicolaou, I.; Tsikna, L.; Roberts, C.; Hughes-Thomas, Z.; Walford, J.; Gibson, D.; Warrack, J.; Smal, J.; Verrijk, R.; Miller, P.E.; Nork, T.M.; Prusakiewicz, J.; Streit, T.; Sorden, S.; Struble, C.; Christian, B.; Catchpole, I.R. Single ocular injection of a sustainedrelease anti-VEGF de-livers 6months pharmacokinetics and efficacy in a primate laser CNV model. J. Control. Release, 2016, 244(Pt A), 1-13.
[http://dx.doi.org/10.1016/j.jconrel.2016.10.026] [PMID: 27810558]
[101]
House, S.E.D.W. House, S.E.D.W. Preclinical studies show pSivida’s Durasert implant delivering TKI just as effective as injection of FDA-approved biologic in wet AMD; shares up 5%, Seek-ing Alpha. (400AD). Available at: https://seekingalpha.com/news/3191730-preclinical-studies-show-psividas-durasert-implant-delivering-tki-just-effective-injection (Accessed: September 23, 2018)
[102]
Chakravarthy, U.; Bailey, C.; Brown, D.; Campochiaro, P.; Chittum, M.; Csaky, K.; Tufail, A.; Yates, P.; Cech, P.; Giraudon, M.; Delmar, P.; Szczesny, P.; Sahni, J.; Boulay, A.; Nagel, S.; Fürst-Recktenwald, S.; Schwab, D.; Phase, I. Trial of anti-vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. Ophthalmol. Retina, 2017, 1(6), 474-485.
[http://dx.doi.org/10.1016/j.oret.2017.03.003] [PMID: 31047438]
[103]
CLN-0046: treatment of amd subjects with OTX-TKI. Available at: https://clinicaltrials.gov/ct2/show/NCT03630315 (Accessed: October 2, 2018).
[104]
Rempel, V.; Fuchs, A.; Hinz, S.; Karcz, T.; Lehr, M.; Koetter, U.; Müller, C.E. Magnolia extract, magnolol, and metabolites: activation of cannabinoid cb2 receptors and blockade of the related GPR55. ACS Med. Chem. Lett., 2012, 4(1), 41-45.
[http://dx.doi.org/10.1021/ml300235q] [PMID: 24900561]
[105]
Safety and efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and older with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Available at: https://clinicaltrials.gov/ct2/show/NCT03446144 (Accessed: October 2, 2018).
[106]
McKenzie, J.A.G.; Fruttiger, M.; Abraham, S.; Lange, C.A.K.; Stone, J.; Gandhi, P.; Wang, X.; Bainbridge, J.; Moss, S.E.; Greenwood, J. Apelin is required for non-neovascular remodeling in the retina. Am. J. Pathol., 2012, 180(1), 399-409.
[http://dx.doi.org/10.1016/j.ajpath.2011.09.035] [PMID: 22067912]

Rights & Permissions Print Cite
Article Metrics
111
22
1
© 2024 Bentham Science Publishers | Privacy Policy